Dr Reddy Laboratories
- All
- News
- Videos
-
Antitrust Litigation Filed Against Dr Reddy's Laboratories In US
Dr Reddy's Laboratories Ltd on Tuesday said it is among several generic pharmaceutical companies, including Celgene and Bristol Myers Squibb, against which an antitrust litigation has been filed in the US.
-
Dr Reddy's To Earmark Rs 1,500 Crore Capex For Biosimilars, Injectables
Dr Reddy's Laboratories has earmarked a capex of around Rs 1,500 crore for FY23 with major part of it slated to go into building capacities for its biosimilar and injectable businesses.
-
Dr Reddy's, Cipla, Aurobindo Units Recall Products From US Market
Leading drug firms Dr Reddy's Laboratories, Cipla and Aurobindo Pharma are recalling different products in the US market for various issues, according to the US Food and Drug Administration.
-
Dr Reddy's Plans 'Business Continuity' In Russia
Indian pharmaceutical major Dr. Reddy's Laboratories Ltd said on Wednesday it was focused on employee safety and business continuity in and around Russia, despite many Western companies pulling out from Russia in recent days.
-
Dr Reddy's Laboratories Gets FDA Approval, Launches Drug In US Market
Dr Reddy's Laboratories on Wednesday said it has launched a vasopressin injection, which is used to control frequent urination, increased thirst, and loss of water caused by diabetes, in the American market.
-
Proposal For Sputnik Light As Covid Booster Submitted To Drug Regulator
Drug major Dr Reddy's Laboratories has submitted a proposal to the Drugs Controller General of India (DCGI) to register Sputnik Light vaccine as a booster dose against COVID-19, a top company official has said.
-
Trying To Bring Vaccine For 12-18 Age Group To India: Dr Reddy's
Dr Reddy's Laboratories on Friday said it is in discussions with the Indian drug regulator to bring Russia's Sputnik M, a COVID-19 vaccine for the 12 to18-year-old category, to India.
-
Merck's Anti- Covid Pill 'Molflu' 5-Day Course To Cost Rs 1,400 In India
Drugmaker Dr Reddy's Laboratories Ltd will launch its generic version of Merck's antiviral COVID-19 pill, molnupiravir.
-
Pharma Stocks Gain After Centre Approves Use Of COVID Pill Molnupiravir
Pharma Stocks Today: Pharmaceutical shares such as Cipla, Dr Reddy's Laboratories, Torrent Pharma, Sun Pharma Industries gained around two per cent each on Wednesday
-
Why Top Drugmaker Is Surprisingly Downbeat About Covid Pill, Sputnik Shot
For a drugmaker licensed to produce Merck & Co.'s promising Covid-19 pill and sell Russia's Sputnik V shot, Dr Reddy's Laboratories Ltd. is surprisingly mellow about the rewards it expects from these medical breakthroughs.
-
Dr Reddy's Open To Making Pfizer Covid Pill
Dr Reddy's Laboratories, one of a handful of Indian drug companies licensed to make a new COVID-19 pill developed by Merck, said on Monday it was open to making a similar pill from Pfizer, thought to be even more effective.
-
Dr Reddy's Laboratories Net Profit Rises 30% To Rs 992 Crore In September Quarter
Dr Reddy's Q2 Results: The pharma major's revenue from operations in the second quarter of the current fiscal stood at Rs 5,763 crore, compared to Rs 4,896 crore in the same quarter last year
-
Dr Reddy's Hopes To Submit Sputnik V Light Trial Data To Drug Regulator In November
Dr Reddy's Laboratories Ltd is expected to submit Phase 3 trials data of single-dose Russian COVID-19 vaccine Sputnik Light to the Indian drug regulator next month, even as the city-based firm is getting ready to conduct trials of the jab in 2 to 18
-
Stocks To Watch: Wipro, Dr Reddy's Laboratories, EID Parry India
Dr Reddy's Laboratories has started supplying the first dose component of the Russian COVID-19 vaccine Sputnik V to partner hospitals all over the country
-
Stocks To Watch: Ashoka Buildcon, Dr Reddy's Laboratories, ICICI Lombard
Ashoka Buildcon has received the letter of award from Adani Road Transport for the execution of civil and associated works of the national corridor NH-19 from Pangarh to Palsit in West Bengal
-
Antitrust Litigation Filed Against Dr Reddy's Laboratories In US
Dr Reddy's Laboratories Ltd on Tuesday said it is among several generic pharmaceutical companies, including Celgene and Bristol Myers Squibb, against which an antitrust litigation has been filed in the US.
-
Dr Reddy's To Earmark Rs 1,500 Crore Capex For Biosimilars, Injectables
Dr Reddy's Laboratories has earmarked a capex of around Rs 1,500 crore for FY23 with major part of it slated to go into building capacities for its biosimilar and injectable businesses.
-
Dr Reddy's, Cipla, Aurobindo Units Recall Products From US Market
Leading drug firms Dr Reddy's Laboratories, Cipla and Aurobindo Pharma are recalling different products in the US market for various issues, according to the US Food and Drug Administration.
-
Dr Reddy's Plans 'Business Continuity' In Russia
Indian pharmaceutical major Dr. Reddy's Laboratories Ltd said on Wednesday it was focused on employee safety and business continuity in and around Russia, despite many Western companies pulling out from Russia in recent days.
-
Dr Reddy's Laboratories Gets FDA Approval, Launches Drug In US Market
Dr Reddy's Laboratories on Wednesday said it has launched a vasopressin injection, which is used to control frequent urination, increased thirst, and loss of water caused by diabetes, in the American market.
-
Proposal For Sputnik Light As Covid Booster Submitted To Drug Regulator
Drug major Dr Reddy's Laboratories has submitted a proposal to the Drugs Controller General of India (DCGI) to register Sputnik Light vaccine as a booster dose against COVID-19, a top company official has said.
-
Trying To Bring Vaccine For 12-18 Age Group To India: Dr Reddy's
Dr Reddy's Laboratories on Friday said it is in discussions with the Indian drug regulator to bring Russia's Sputnik M, a COVID-19 vaccine for the 12 to18-year-old category, to India.
-
Merck's Anti- Covid Pill 'Molflu' 5-Day Course To Cost Rs 1,400 In India
Drugmaker Dr Reddy's Laboratories Ltd will launch its generic version of Merck's antiviral COVID-19 pill, molnupiravir.
-
Pharma Stocks Gain After Centre Approves Use Of COVID Pill Molnupiravir
Pharma Stocks Today: Pharmaceutical shares such as Cipla, Dr Reddy's Laboratories, Torrent Pharma, Sun Pharma Industries gained around two per cent each on Wednesday
-
Why Top Drugmaker Is Surprisingly Downbeat About Covid Pill, Sputnik Shot
For a drugmaker licensed to produce Merck & Co.'s promising Covid-19 pill and sell Russia's Sputnik V shot, Dr Reddy's Laboratories Ltd. is surprisingly mellow about the rewards it expects from these medical breakthroughs.
-
Dr Reddy's Open To Making Pfizer Covid Pill
Dr Reddy's Laboratories, one of a handful of Indian drug companies licensed to make a new COVID-19 pill developed by Merck, said on Monday it was open to making a similar pill from Pfizer, thought to be even more effective.
-
Dr Reddy's Laboratories Net Profit Rises 30% To Rs 992 Crore In September Quarter
Dr Reddy's Q2 Results: The pharma major's revenue from operations in the second quarter of the current fiscal stood at Rs 5,763 crore, compared to Rs 4,896 crore in the same quarter last year
-
Dr Reddy's Hopes To Submit Sputnik V Light Trial Data To Drug Regulator In November
Dr Reddy's Laboratories Ltd is expected to submit Phase 3 trials data of single-dose Russian COVID-19 vaccine Sputnik Light to the Indian drug regulator next month, even as the city-based firm is getting ready to conduct trials of the jab in 2 to 18
-
Stocks To Watch: Wipro, Dr Reddy's Laboratories, EID Parry India
Dr Reddy's Laboratories has started supplying the first dose component of the Russian COVID-19 vaccine Sputnik V to partner hospitals all over the country
-
Stocks To Watch: Ashoka Buildcon, Dr Reddy's Laboratories, ICICI Lombard
Ashoka Buildcon has received the letter of award from Adani Road Transport for the execution of civil and associated works of the national corridor NH-19 from Pangarh to Palsit in West Bengal
